Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 279

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial

Jeger, Raban V, Farah, Ahmed, Ohlow, Marc-Alexander, Mangner, Norman, Möbius-Winkler, Sven, Weilenmann, Daniel, Wöhrle, Jochen, Stachel, Georg, Markovic, Sinisa, Leibundgut, Gregor, Rickenbacher, Peter, Osswald, Stefan, Cattaneo, Marco, Gilgen, Nicole, Kaiser, Christoph, Scheller, Bruno, Ammann, Peter, Awad, Belal, Baumgartner, Margarete, Boehm, Michael, Bohl, Steffen, Bruch, Leonhard, Buckert, Dominik, Buser, Peter, Butter, Christian, Clever, Yvonne P., Cremers, Bodo, Cuculi, Florim, Dannberg, Gudrun, Erne, Paul, Ewen, Sebastian, Fahrni, Gregor, Franz, Marcus, Haager, Philipp, Harder-Allgoewer, Andrea, Hoffmann, Andreas, Höllriegel, Robert, Hölschermann, Frank, Jerichow, Timo, Joerg, Lucas, Kapos, Ioannis, Keweloh, Boris, Kherad, Behrouz, Kühne, Michael, Lauer, Bernward, Lenk, Karsten, Lenz, Corinna, Von Lewinski, Dirk, Linke, Axel, Luha, Olev, Maeder, Micha, Mahfoud, Felix, Mueller, Christian, Neuss, Michael, Niederl, Ella, Noutsias, Michel, Nuessli, Dominique, Oenal, Ismet, Otto, Sylvia, Paliskyte, Rima, Perl, Sabine, Pieske, Burkert, Plicht, Bjoern, Poerner, Tudor C, Richter, Stefan, Rickli, Hans, Riede, Florian, Roelli, Hans, Roettgen, Alexandra, Rohner, Franziska, Schirmer, Stephan, Schmidt, Albrecht, Schreiber, Matthias, Seidel, Mirko, Stephan, Frank-Peter, Sticherling, Christian, Struck, Berthold, Surber, Ralf, Tambor, Grit, Toggweiler, Stefan, Trachsel, Lukas, Twerenbold, Raphael, Wagner, Andreas, Wein, Bastian, Winkler, Sebastian, Winzer, Ephraim, Wolf, Alexander, Zellweger, Michael, Krackhardt, Florian, Zweiker, Robert · 2020 · The Lancet

Abstract

BACKGROUND In the treatment of de-novo coronary small vessel disease, drug-coated balloons (DCBs) are non-inferior to drug-eluting stents (DESs) regarding clinical outcome up to 12 months, but data beyond 1 year is sparse. We aimed to test the long-term efficacy and safety of DCBs regarding clinical endpoints in an all-comer population undergoing percutaneous coronary intervention. METHODS In this prespecified long-term follow-up of a multicentre, randomised, open-label, non-inferiority trial, patients from 14 clinical sites in Germany, Switzerland, and Austria with de-novo lesions in coronary vessels <3 mm and an indication for percutaneous coronary intervention were randomly assigned 1:1 to DCB or second-generation DES and followed over 3 years for major adverse cardiac events (ie, cardiac death, non-fatal myocardial infarction, and target-vessel revascularisation [TVR]), all-cause death, probable or definite stent thrombosis, and major bleeding (Bleeding Academic Research Consortium bleeding type 3-5). Analyses were performed on the full analysis set according to the modified intention-to-treat principle. Dual antiplatelet therapy was recommended for 1 month after DCB and 6 months after DES with stable symptoms, but 12 months with acute coronary syndromes. The study is registered with ClinicalTrials.gov, NCT01574534 and is ongoing. FINDINGS Between April 10, 2012, and Feb 1, 2017, of 883 patients assessed, 758 (86%) patients were randomly assigned to the DCB group (n=382) or the DES group (n=376). The Kaplan-Meier estimate of the rate of major adverse cardiac events was 15% in both the DCB and DES groups (hazard ratio [HR] 0·99, 95% CI 0·68-1·45; p=0·95). The two groups were also very similar concerning the single components of adverse cardiac events: cardiac death (Kaplan-Meier estimate 5% vs 4%, HR 1·29, 95% CI 0·63-2·66; p=0·49), non-fatal myocardial infarction (both Kaplan-Meier estimate 6%, HR 0·82, 95% CI 0·45-1·51; p=0·52), and TVR (both Kaplan-Meier estimate 9%, HR 0·95, 95% CI 0·58-1·56; p=0·83). Rates of all-cause death were very similar in DCB versus DES patients (both Kaplan-Meier estimate 8%, HR 1·05, 95% CI 0·62-1·77; p=0·87). Rates of probable or definite stent thrombosis (Kaplan-Meier estimate 1% vs 2%; HR 0·33, 95% CI 0·07-1·64; p=0·18) and major bleeding (Kaplan-Meier estimate 2% vs 4%, HR 0·43, 95% CI 0·17-1·13; p=0·088) were numerically lower in DCB versus DES, however without reaching significance. INTERPRETATION There is maintained efficacy and safety of DCB versus DES in the treatment of de-novo coronary small vessel disease up to 3 years. FUNDING Swiss National Science Foundation, Basel Cardiovascular Research Foundation, and B Braun Medical.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(20)32173-5

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Metadata

Authors
Jeger, R. V., Farah, A., Ohlow, M.-A., Mangner, N., Möbius-Winkler, S., Weilenmann, D., Wöhrle, J., Stachel, G., Markovic, S., Leibundgut, G., Rickenbacher, P., Osswald, S., Cattaneo, M., Gilgen, N., Kaiser, C., Scheller, B., Ammann, P., Awad, B., Baumgartner, M., Boehm, M., Bohl, S., Bruch, L., Buckert, D., Buser, P., Butter, C., Clever, Y. P., Cremers, B., Cuculi, F., Dannberg, G., Erne, P., Ewen, S., Fahrni, G., Franz, M., Haager, P., Harder-Allgoewer, A., Hoffmann, A., Höllriegel, R., Hölschermann, F., Jerichow, T., Joerg, L., Kapos, I., Keweloh, B., Kherad, B., Kühne, M., Lauer, B., Lenk, K., Lenz, C., Von Lewinski, D., Linke, A., Luha, O., Maeder, M., Mahfoud, F., Mueller, C., Neuss, M., Niederl, E., Noutsias, M., Nuessli, D., Oenal, I., Otto, S., Paliskyte, R., Perl, S., Pieske, B., Plicht, B., Poerner, T. C., Richter, S., Rickli, H., Riede, F., Roelli, H., Roettgen, A., Rohner, F., Schirmer, S., Schmidt, A., Schreiber, M., Seidel, M., Stephan, F.-P., Sticherling, C., Struck, B., Surber, R., Tambor, G., Toggweiler, S., Trachsel, L., Twerenbold, R., Wagner, A., Wein, B., Winkler, S., Winzer, E., Wolf, A., Zellweger, M., Krackhardt, F., & Zweiker, R.
Venue
The Lancet
Publisher
Elsevier BV
Published
2020-11
Volume
396
Issue
10261
Pages
1504-1510
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W3094011070
Cited by
279
References
17
FWCI
19.30
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial. https://app.cochat.ai/papers/10.1016/s0140-6736(20)32173-5
The paper
Jeger, R. V., Farah, A., Ohlow, M.-A., Mangner, N., Möbius-Winkler, S., Weilenmann, D., Wöhrle, J., Stachel, G., Markovic, S., Leibundgut, G., Rickenbacher, P., Osswald, S., Cattaneo, M., Gilgen, N., Kaiser, C., Scheller, B., Ammann, P., Awad, B., Baumgartner, M., . . . Zweiker, R. (2020). Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial. The Lancet. https://doi.org/10.1016/s0140-6736(20)32173-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.